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Abstract Tumor necrosis factor K (TNFK) induces apoptosis of
a variety of tumor cell types. The anti-tumor effect of TNFK is
often augmented by interferon (IFN) Q. We hypothesized that
IFNK, which shares many biological activities with IFNQ, might
also synergize with TNFK for the induction of tumor cell death.
We tested our hypothesis using ME-180 human cervical cancer
cells exposed to either IFNK or TNFK alone or both. We
analyzed the death of ME-180 cells by biochemical and
cytological means, and investigated the molecular mechanism
underlying cytotoxic synergism between the two cytokines. We
found that (i) IFNK/TNFK synergistically induced apoptosis of
ME-180 cells, which was accompanied by activation of caspases-
3 and -8; (ii) IFNK induced signal transducer and activator of
transcription (STAT) 1 phosphorylation, and transfection of
phosphorylation-defective STAT1 dominant-negative mutant
inhibited IFNK/TNFK-induced apoptosis ; (iii) inhibition of
nuclear factor UB (NF-UB) by proteasome inhibitor MG-132
sensitized ME-180 cells to TNFK alone; (iv) IFNK treatment
attenuated TNFK-induced NF-UB reporter activity, while it did
not inhibit DNA binding of NF-UB. Taken collectively, our
results indicate that IFNK sensitizes ME-180 cells to TNFK-
induced apoptosis by inhibiting TNFK-mediated cytoprotective
NF-UB activation, and this sensitizing effect of IFNK is mediated
through a STAT1-dependent pathway. ß 2001 Published by
Elsevier Science B.V. on behalf of the Federation of European
Biochemical Societies.
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1. Introduction
Tumor necrosis factor K (TNFK) induces apoptosis of a
variety of tumor cell types. The anti-tumor e¡ect of TNFK
is often augmented by interferon (IFN) Q [1]. We and others
have demonstrated that TNFK and IFNQ synergistically in-
duce apoptosis of tumor cells [2^5]. IFNQ exerts its biological
activities by binding to cell surface receptors. Upon ligation of
IFNQ receptors, signal transducer and activator of transcrip-
tion (STAT) 1 is phosphorylated, homodimerized, and trans-
located into the nucleus to activate transcription of numerous
IFNQ-responsive genes [6]. Through the up-regulation of these
genes, IFNQ exerts its biological e¡ects such as induction of
anti-viral state, inhibition of cellular proliferation, and activa-
tion of mononuclear phagocytes and vascular endothelial
cells. Many of these biological e¡ects of IFNQ are shared by
IFNK. Both IFNQ and IFNK are anti-proliferative, up-regu-
late class I MHC expression, and inhibit viral replication.
Synergism between IFNK and IFNQ has also been reported
[7,8]. Signaling cross talk between the two types of IFNs in
caveolar membrane domains has been proposed as a molec-
ular basis for their overlapping functions and synergism [9].
However, dissimilar or contrasting e¡ects of the two types of
IFNs have also been reported. While IFNQ enhances the ex-
pression of class II MHC molecules, IFNK inhibits their ex-
pression [6,10]. IFNK produced by natural IFN-producing
cells upon viral infection plays an important role in the ini-
tiation of adaptive immunity [11,12]. IFNQ has other immu-
nomodulatory activities that are not shared by IFNK, such as
promotion of T cell di¡erentiation, B cell class switching, and
activation of mononuclear phagocytes, neutrophils, and vas-
cular endothelial cells. Signal transduction by IFNQ and IFNK
also involves similar and dissimilar pathways. Unlike IFNQ
that activates only STAT1, IFNK activates STAT2 as well
as STAT1. After binding to speci¢c receptors, IFNK induces
auto- and trans-phosphorylation of Jak1 and Tyk2. Activated
Jak1 and Tyk2 catalyze the sequential phosphorylation of
STAT2 and STAT1. Heterodimer of activated STAT1 and
STAT2 or heterotrimer of STAT1, STAT2, and p48, a mem-
ber of the interferon regulatory factor (IRF) family of tran-
scription factors, translocates into the nucleus for transcrip-
tional activation of target genes [13]. These slight di¡erences
in signaling pathways between IFNQ and IFNK might be the
molecular basis for some of the distinct biological activities
observed. Compared to IFNQ, the role of IFNK with respect
to the synergism with TNFK in tumor cell destruction has not
been thoroughly investigated. Several previous reports, how-
ever, suggested the possible synergism between IFNK and
TNFK in the induction of tumor cell death in vitro as well
as in vivo [14^17]. Nevertheless, the underlying mechanisms of
IFNK and IFNQ in their synergism with TNFK may be di¡er-
ent.
We have recently reported synergism between IFNQ and
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TNFK in the induction of ME-180 human cervical cancer cell
apoptosis and presented evidence that IFNQ inhibits TNFK-
induced cytoprotective nuclear factor UB (NF-UB) activation
[5]. In the current work, we utilized the same model to inves-
tigate whether IFNK synergizes with TNFK to induce tumor
cell apoptosis in a manner similar to IFNQ. We also studied
the possible regulation of NF-UB activity by IFNK in an at-
tempt to understand the molecular mechanism underlying the
cytotoxic synergism between IFNK/TNFK.
2. Materials and methods
2.1. Cell line and reagents
ME-180 human cervical cancer cell line was obtained from ATCC
(Manassas, VA, USA) and grown in Dulbecco’s modi¢ed Eagle’s
medium containing 10% fetal bovine serum, 2 mM glutamine, and
penicillin^streptomycin (Gibco-BRL, Gaithersburg, MD, USA). Re-
combinant human IFNQ and TNFK were purchased from RpD Sys-
tems (Minneapolis, MN, USA). Recombinant human IFNK was gen-
erously provided by Dr. Young-Ju Ha at Mogam Institute (Yongin,
South Korea). Proteasome inhibitor, MG-132 (carbobenzoxyl-leucin-
yl-leucinyl-leucinal-H, also called Z-LLL), was from Calbiochem (La
Jolla, CA, USA). All other chemicals were obtained from Sigma
Chemical Co. (St. Louis, MO, USA), unless stated otherwise.
2.2. Assessment of cytotoxicity by 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay
Cells (3U104/well) were seeded in 96-well plates and treated with
various combinations of cytokines for indicated time periods. In some
experiments, cells were pretreated with caspase inhibitors or MG-132
for 1 h before cytokine treatment. After cytokine treatment, the me-
dium was removed and MTT (0.5 mg/ml) was added, followed by
incubation at 37‡C for 2 h in a CO2 incubator. After a brief centri-
fugation, supernatants were carefully removed and DMSO was added.
After insoluble crystals were completely dissolved, absorbance at 540
nm was measured using a Thermomax microplate reader (Molecular
Devices). Results were presented as means þ S.E.M. (n = 3).
2.3. Morphological and biochemical analysis of apoptosis
Morphological changes in the nuclear chromatin of cells under-
going apoptosis were detected by staining with 2.5 Wg/ml of bisbenzi-
mide Hoechst 33342 £uorochrome (Molecular Probes, Eugene, OR,
USA), followed by examination on a £uorescence microscope. Oligo-
nucleosomal cleavage of genomic DNA was detected by agarose gel
electrophoresis. In brief, genomic DNA isolated as previously de-
scribed [18] was subjected to 1.5% agarose gel electrophoresis, fol-
lowed by ethidium bromide staining.
2.4. Assessment of caspase activity
Caspase-3 or -8-like activity was measured using a caspase assay kit
(Pharmingen, San Diego, CA, USA) according to the supplier’s in-
struction. In brief, caspase-3 or -8 £uorogenic substrates (Ac-DEVD-
AMC or Ac-IETD-AMC) were incubated with cytokine-treated cell
lysates for 1 h at 37‡C, then AMC liberated from Ac-DEVD-AMC or
Ac-IETD-AMC was measured using a £uorometric plate reader with
an excitation wavelength of 380 nm and an emission wavelength of
420^460 nm.
2.5. Western blot analysis
Cells were lysed in triple-detergent lysis bu¡er (50 mM Tris^HCl,
pH 8.0, 150 mM NaCl, 0.02% sodium azide, 0.1% sodium dodecyl
sulfate (SDS), 1% NP-40, 0.5% sodium deoxycholate, 1 mM phenyl-
methylsulfonyl £uoride). Protein concentration in cell lysates was de-
termined using a Bio-Rad protein assay kit. An equal amount of
protein for each sample was separated by 10% SDS^PAGE and trans-
ferred to Hybond ECL nitrocellulose membranes (Amersham, Buck-
inghamshire, UK). The membranes were blocked with 5% skim milk
and sequentially incubated with primary antibodies (rabbit anti-hu-
man STAT1 and anti-human phospho-STAT1; New England Bio-
labs, Beverly, MA, USA) and horseradish peroxidase-conjugated sec-
ondary antibodies (anti-rabbit IgG, Amersham), followed by ECL
detection (Amersham).
2.6. Transient transfection
ME-180 cells in 6-well plates were co-transfected with 1 Wg of dom-
inant-negative mutant of human STAT1 cDNA (kindly provided by
Dr. Hirano, Osaka University, Japan) together with 0.2 Wg of lacZ
gene (pCH110, Pharmacia) using lipofectAMINE reagent (Gibco-
BRL). At 48 h after the transfection, cells were treated with cytokines.
After another 48 h, the cells were ¢xed with 0.5% glutaraldehyde for
10 min at room temperature and stained with X-gal (1 mg/ml) in
4 mM potassium ferricyanide/4 mM potassium ferrocyanide/2 mM
magnesium chloride at 37‡C for detection of blue cells. At least 200
blue cells were counted for each experiment, and transfection e⁄-
ciency was 10^35%. Results were presented as means þ S.E.M. (n = 3).
2.7. NF-UB reporter assay
NF-UB reporter activity was measured using Dual-Luciferase Re-
porter Assay System (Promega, Madison, WI, USA). In brief, ME-
180 cells in 12-well plates were co-transfected with 0.5 Wg of NF-UB-
responsive reporter gene construct carrying two copies of UB sequen-
ces linked to luciferase gene (IgGU NF-UB-luciferase, generously pro-
vided by Dr. G.D. Rosen, Stanford University, Stanford, CA, USA)
[19] together with 0.1 Wg of Renilla luciferase gene under HSV thymi-
dine kinase promoter (pRL-TK, Promega) using lipofectAMINE re-
agent (Gibco-BRL). At 24 h after the transfection, cells were treated
with cytokines. After 5 h, activities of ¢re£y luciferase and Renilla
luciferase in transfected cells were measured sequentially from a single
sample using Dual-Luciferase Reporter Assay System (Promega). Re-
sults were presented as ¢re£y luciferase activity normalized to Renilla
luciferase activity. Results were presented as means þ S.E.M. (n = 3).
2.8. Electrophoretic mobility shift assay
Nuclear extracts were prepared from ME-180 cells treated with
cytokines as previously described [20]. Synthetic double-strand oligo-
nucleotides of consensus NF-UB binding sequence, GAT CCC AAC
GGC AGG GGA (Promega), were end-labeled with [Q-32P]ATP using
T4 polynucleotide kinase. Nuclear extract was incubated with the
labeled probe in the presence of poly(dI-dC) in a binding bu¡er con-
taining 20 mM N-2-hydroxyethylpiperazine-NP-2-ethanesulfonic acid
at room temperature for 30 min. For supershift assays, a total of 0.2
Wg of antibodies against p65 subunit of NF-UB were included in the
reaction. DNA^protein complexes were resolved by electrophoresis in
a 5% non-denaturing polyacrylamide gel, which was dried and visu-
alized by autoradiography.
3. Results
3.1. IFNK and TNFK synergistically induced the apoptosis of
ME-180 cells
Cytotoxicity of IFNK and TNFK toward ME-180 cells was
evaluated either alone or in combination. While neither cyto-
kines alone exhibited signi¢cant cytotoxicity, the combination
of the two cytokines signi¢cantly reduced ME-180 cell viabil-
ity (Fig. 1A). The cytokine cytotoxicity was dependent on the
dose of IFNK used (Fig. 1B). However, the use of more than
10 ng/ml of TNFK did not further increase the cytotoxicity
(data not shown). The reduction of cell viability was due to
apoptosis as demonstrated by Hoechst 33342 staining of nu-
clei and electrophoresis of genomic DNA. IFNK/TNFK treat-
ment induced nuclear condensation and fragmentation (Fig.
1C) and led to oligonucleosomal cleavage of genomic DNA
(Fig. 1A, inset), which are hallmarks of apoptosis. We next
investigated whether the activation of caspases is involved in
the IFNK/TNFK-induced apoptosis of ME-180 cells. Cyto-
kine-induced apoptosis of ME-180 cells was accompanied by
the induction of caspases-3 and -8-like activities as demon-
strated by the cleavage of Ac-DEVD-AMC and Ac-IETD-
AMC, respectively, in IFNK/TNFK-treated cells (Fig. 2).
These results indicate that IFNK/TNFK-induced death of
ME-180 cells is a typical apoptosis associated with caspase
activation.
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3.2. IFNK-induced STAT1 activation is critically involved in
IFNK/TNFK synergism
Because IFNK induces the expression of a variety of genes
via STAT1/STAT2 or STAT1/STAT2/p48, and biological ac-
tivities of IFNK are mostly mediated through up-regulation of
these genes, we hypothesized that IFNK may sensitize ME-180
cells to TNFK-mediated cytotoxicity in a manner dependent
on STAT1. We tested this hypothesis by investigating STAT1
induction and phosphorylation in ME-180 cells treated with
the cytokines, and evaluated the role of STAT1 in cytotoxic
synergism of IFNK/TNFK employing dominant-negative mu-
tant of STAT1. IFNK, but not TNFK, induced STAT1 ex-
pression and its phosphorylation (Fig. 3A), and the transfec-
tion of phosphorylation-defective dominant-negative mutant
of STAT1 signi¢cantly inhibited IFNK/TNFK-induced ME-
180 cell death, indicating that IFNK-induced STAT1 activa-
tion is critical for the induction of TNFK susceptibility (Fig.
3B).
3.3. Inhibition of cytoprotective NF-UB activity by IFNK
TNFK initiates both death and survival signals, and NF-UB
activation is believed to play a pivotal role in TNFK-induced
survival signal transduction pathway [21^24]. In order to
understand how IFNK induces susceptibility to TNFK-in-
duced cytotoxicity, we examined the role of NF-UB in ME-
180 cell death and its possible regulation by IFNK. Treatment
of ME-180 cells with a proteasome inhibitor (MG-132), which
is known to inhibit NF-UB activation [25], rendered the cells
sensitive to TNFK-induced apoptosis (Fig. 4A), suggesting the
cytoprotective role of NF-UB. Moreover, NF-UB reporter as-
says indicated that IFNK pretreatment attenuated TNFK-in-
duced NF-UB activity (Fig. 4B). These results altogether in-
dicate that IFNK synergizes with TNFK for the induction of
ME-180 cell apoptosis by inhibiting TNFK-induced cytopro-
tective NF-UB activity. IFNK pretreatment, however, did not
inhibit DNA binding of NF-UB induced by TNFK treatment
(Fig. 5).
4. Discussion
Here, we report that IFNK sensitizes ME-180 cells to
Fig. 1. IFNK/TNFK synergistically induces ME-180 cell apoptosis. A combination of IFNK (100 U/ml) and TNFK (10 ng/ml), but not either
cytokines alone, induced ME-180 cell death. Cell viability was assessed by MTT assays after treatment with the cytokines for 48 h (A). Viabil-
ity of untreated cells was set to 100%. Together with TNFK (10 ng/ml), IFNK dose-dependently decreased the viability of ME-180 cells (B).
However, concentrations of IFNK higher than 100 U/ml did not further increase cytotoxicity. Induction of ME-180 cell death was due to apo-
ptosis, because the cytokine treatment for 48 h induced chromatin condensation as detected by Hoechst 33342 staining (C) and oligonucleoso-
mal cleavage of genomic DNA as determined by gel electrophoresis and ethidium bromide staining of genomic DNA (A inset: lane 1, none;
lane 2, IFNK (100 U/ml) and TNFK (10 ng/ml)).
Fig. 2. Activation of caspase-3 and -8-like activities by IFNK/TNFK
in ME-180 cells. IFNK/TNFK treatment (IFNK, 100 U/ml; TNFK,
10 ng/ml) induced cleavage of Ac-DEVD-AMC and Ac-IETD-
AMC, indicating activation of caspase-3 and -8-like activity, respec-
tively.
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TNFK-induced apoptosis by inhibiting cytoprotective NF-UB
activation in a manner dependent on STAT1. This is sup-
ported by several lines of evidence. First, the combination
of IFNK and TNFK, but not either cytokines alone, induced
a signi¢cant cytotoxicity toward ME-180 cells. Second, IFNK
induced STAT1 phosphorylation, and transfection of phos-
phorylation-defective STAT1 dominant-negative mutant in-
hibited IFNK/TNFK-induced apoptosis. Third, the inhibition
of NF-UB sensitized ME-180 cells to TNFK alone. Finally,
IFNK treatment attenuated TNFK-induced NF-UB reporter
activity. These results suggest that TNFK alone does not in-
duce a signi¢cant cell death, because it initiates both survival
and death signals in ME-180 cells. However, when combined
with IFNK, TNFK may induce apoptosis, as IFNK inhibits
the survival signal pathway represented by NF-UB. This may
be the molecular basis for the cytotoxic synergism between
IFNK and TNFK in ME-180 cells. A cytoprotective role of
NF-UB in ME-180 cells was demonstrated by MG-132, a pro-
teasome inhibitor. Although treatment of ME-180 cells with
MG-132 alone at high concentrations induced cytotoxicity to
a certain extent, 0.5 WM of MG-132, which was not signi¢-
cantly toxic by itself, greatly increased TNFK-induced cyto-
toxicity. A cytoprotective role of NF-UB in ME-180 cells was
also demonstrated in our previous work, where inhibition of
NF-UB by transfection of dominant-negative mutant of IUB
(super-repressor of NF-UB) sensitized ME-180 cells to TNFK-
induced cell death [5].
IFNK/TNFK synergism in the induction of ME-180 cell
apoptosis was dependent on STAT1. IFNK treatment induced
STAT1 expression and its activation. Blockade of STAT1
signaling by dominant-negative mutant of STAT1 suppressed
IFNK/TNFK-induced cell death. We have previously demon-
strated that IFNQ also synergizes with TNFK for the induc-
tion of ME-180 cell apoptosis, and IFNQ also activates the
STAT1 signaling pathway in ME-180 cells : IFNQ induces
STAT1 expression and its phosphorylation [5]. Thus, in
ME-180 cells, both IFNQ and IFNK appear to activate the
STAT1 signaling pathway. The cytotoxic priming role of
IFNK in IFNK/TNFK synergism presented in the current
study does not seem to be restricted to type I IFN. Rather,
the STAT1 signaling pathway which can be initiated by either
type I or type II IFN appears to be critical for the cytotoxic
synergism with TNFK. A central role of STAT1 in IFNK as
Fig. 3. A key role for STAT1 signaling in IFNK/TNFK synergism in ME-180 cells. (A) Western blot analyses demonstrated that treatment of
ME-180 cells with IFNK induced STAT1 expression (24 h treatment) as well as its phosphorylation (30 min treatment). However, TNFK did
not induce the expression of STAT1 (data not shown). IFNQ was used for comparison. Concentrations of cytokines used are as follows: IFNQ
and IFNK, 100 U/ml; TNFK, 10 ng/ml. (B) Transient transfection of phosphorylation-defective STAT1 dominant-negative mutant (DN
STAT1) signi¢cantly inhibited IFNK/TNFK cytotoxicity, as demonstrated by counting blue cells co-expressing lacZ at 48 h after cytokine treat-
ment (IFNK, 100 U/ml; TNFK, 10 ng/ml). The number of blue cells upon transfection with an empty vector (Vec) without TNFK treatment
was set to 100%.
Fig. 4. Inhibition of cytoprotective NF-UB by IFNK. (A) Inhibition
of NF-UB by proteasome inhibitor MG-132 sensitized ME-180 cells
to TNFK. ME-180 cells were treated with increasing concentrations
of MG-132 alone or in combination with TNFK (10 ng/ml) for 48
h, and then cell viability was assessed by MTT assays. (B) NF-UB
reporter assays revealed that pretreatment of ME-180 cells with
IFNK (24 h, 100 U/ml) inhibited TNFK-induced NF-UB activity.
Transiently transfected cells were treated with cytokines for the indi-
cated time period before NF-UB reporter assays.
Fig. 5. No signi¢cant e¡ects of IFNK on DNA binding of NF-UB
protein. IFNK pretreatment (10^500 U/ml, 24 h) did not signi¢-
cantly a¡ect TNFK (45 min)-induced UB sequence binding of NF-
UB proteins (lanes 3^5). The identity of DNA-complexed proteins
was con¢rmed by supershift assays using antibodies against p65
subunit of NF-UB (lane 6).
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well as IFNQ signaling observed in our work is in agreement
with previous gene ablation studies. STAT1-de¢cient mice
showed a complete lack of responsiveness to both IFNK
and IFNQ [26,27].
In the current work, we demonstrated that IFNK inhibited
NF-UB reporter activity, without suppressing DNA binding of
NF-UB. Our previous work demonstrated that IFNQ also sen-
sitized ME-180 cells to TNFK-induced apoptosis by inhibiting
NF-UB-mediated activation of anti-apoptosis or survival sig-
nals [5]. Like IFNK, IFNQ did not a¡ect TNFK-induced DNA
binding of NF-UB or nuclear translocation of NF-UB p65,
while inhibiting NF-UB-mediated transactivation. In the case
of IFNQ, the STAT1/IRF-1 pathway appeared to be impor-
tant for the inhibition of NF-UB-mediated anti-apoptotic ac-
tivity. IFNQ strongly induced both STAT1 and IRF-1. Partic-
ularly, IRF-1 transfection alone was able to inhibit NF-UB-
mediated transactivation which was abrogated by coactivator
p300 overexpression, suggesting a possible interference be-
tween transcription factors involving competition for a scanty
amount of transcriptional coactivators [5]. However, IFNK
did not induce IRF-1 expression over a low constitutive level
in ME-180 cells (data not shown). IFNK-activated STAT1
may inhibit NF-UB-mediated transactivation through direct
formation of heterodimers with activated STAT2 or hetero-
trimer involving p48, instead of acting through IRF-1,
although the presence of such complexes was not studied in
this investigation. Thus, IFNK and IFNQ may use di¡erent
signaling pathways downstream of STAT1 in their synergism
with TNFK, while the apparent outcome seems to be similar.
IFNK is known as leukocyte IFN, since the main cellular
source of IFNK has been believed to be mononuclear phago-
cytes. Recently, however, CD4CD11c3 type 2 dendritic cell
precursors (pre-DC2s) in human blood have been shown to
produce enormous amounts of IFNK in response to viruses
[11]. These pre-DC2s were suggested to play master roles in
anti-viral immune responses constituting a critical link be-
tween innate and adaptive immunity [12]. Pre-DC2s have
also been demonstrated to secrete signi¢cant amounts of
TNFK and interleukin-6 in addition to IFNK and IFNL after
viral infection [12]. However, in in£ammatory and anti-tumor
immune responses, the main cellular source of TNFK is the
activated mononuclear phagocytes. Thus, when produced to-
gether by activated mononuclear phagocytes and pre-DC2s,
TNFK and IFNK may be able to synergize in the induction of
tumor cell death. This type of synergism between IFNK and
TNFK may be involved in the in vivo tumor surveillance.
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